NASDAQ:RCKT

Rocket Pharmaceuticals Stock Forecast, Price & News

$43.39
-0.41 (-0.94 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$42.93
Now: $43.39
$44.79
50-Day Range
$39.41
MA: $49.32
$57.92
52-Week Range
$13.69
Now: $43.39
$67.48
Volume467,051 shs
Average Volume513,697 shs
Market Capitalization$2.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Rocket Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RCKT
CUSIPN/A
Phone646-440-9100
Employees91
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.10 per share

Profitability

Net Income$-77,270,000.00

Miscellaneous

Market Cap$2.68 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

Is RCKT Stock A Buy or Sell?
April 12, 2021 |  finance.yahoo.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 4.2%
April 12, 2021 |  americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Down to $42.85
April 9, 2021 |  americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 7.2%
April 6, 2021 |  americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) PT Raised to $66.00
April 1, 2021 |  americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 5%
March 30, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

605th out of 2,024 stocks

Pharmaceutical Preparations Industry

282nd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$43.39
-0.41 (-0.94 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

Is Rocket Pharmaceuticals a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rocket Pharmaceuticals stock.
View analyst ratings for Rocket Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Rocket Pharmaceuticals?

Wall Street analysts have given Rocket Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rocket Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Rocket Pharmaceuticals
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its earnings results on Thursday, February, 25th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.56.
View Rocket Pharmaceuticals' earnings history
.

How has Rocket Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Rocket Pharmaceuticals' stock was trading at $15.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RCKT shares have increased by 171.4% and is now trading at $43.39.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RCKT?

14 brokers have issued 1 year price targets for Rocket Pharmaceuticals' stock. Their forecasts range from $33.00 to $100.00. On average, they expect Rocket Pharmaceuticals' stock price to reach $59.18 in the next year. This suggests a possible upside of 36.4% from the stock's current price.
View analysts' price targets for Rocket Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:
  • Mr. Gaurav Shah, CEO, Pres & Director (Age 45, Pay $840.34k)
  • Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO, Exec. VP & Head of Devel. (Age 42, Pay $683.91k)
  • Mr. Carlos Garcia-Parada M.B.A., Chief Financial Officer (Age 56)
  • Mr. John C. Militello, VP of Fin., Sr. Controller, Treasurer & Principal Accounting Officer (Age 48)
  • Dr. Claudine Prowse Ph.D., Sr. VP of Strategy and Head of Investor Relations & Corp. Devel.
  • Ms. Sara Turken, Sr. Director of Legal & Compliance and Corp. Sec.
  • Mr. Jonathan Schwartz, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 57)
  • Dr. Gayatri R. Rao J.D., M.D., Global Program Head of FA, LAD-I & PKD Programs and VP
  • Mr. Raj Prabhakar, Sr. VP & Chief Bus. Officer
  • Mr. Jose Trevejo M.D., Ph.D., Chief Devel. Officer of AAV & Sr. VP

Who are some of Rocket Pharmaceuticals' key competitors?

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include First Midwest Bank Trust Division (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Rocket Pharmaceuticals stock include Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends for Rocket Pharmaceuticals
.

Which institutional investors are buying Rocket Pharmaceuticals stock?

RCKT stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Pacer Advisors Inc.. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel, and Rtw Investments, Lp.
View insider buying and selling activity for Rocket Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $43.39.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals has a market capitalization of $2.68 billion. The biotechnology company earns $-77,270,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals employs 91 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is www.rocketpharma.com.

Where are Rocket Pharmaceuticals' headquarters?

Rocket Pharmaceuticals is headquartered at 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.